Thank you to Guenther Koehne M.D., Ph.D. for detailing the Phase 1b results with LYT-200 in relapsed/refractory high-risk #MyelodysplasticSyndromes (HR-MDS) and #acutemyeloidleukemia at #ESMO26! The presentation highlighted the favorable safety profile and encouraging clinical activity demonstrated in heavily pretreated patients, including 2 MRD-negative complete responses enabling stem cell transplantation in patients with R/R HR-MDS. Learn more about the results and Gallop Oncology's plans to advance LYT-200 into Phase 2 development: bit.ly/4iGJsLW

Today, on #MDSWorldAwarenessDay, we join the global community in raising awareness of #myelodysplasticsyndromes (MDS) and supporting patients and families affected by these diseases. This year’s theme, “Understanding Your Treatment Options,” underscores the importance of education and continued progress in advancing new treatments for patients. This year's observance comes on the heels of an important milestone for our Founded Entity, Gallop Oncology, as Guenther Koehne, MD, PhD, presented Phase 1b results for LYT-200 in relapsed/refractory high-risk MDS and #acutemyeloidleukemia during an oral presentation at #ESMO26 yesterday. We are proud to be part of the broader research community dedicated to advancing new therapeutic approaches for patients with significant unmet medical needs.

Yesterday, members of the PureTech and Gallop Oncology teams participated in #MoveForMDS Boston in support of patients and families affected by #myelodysplasticsyndromes (MDS). We are proud to join the @MDSFoundation and the local MDS community to raise awareness and support continued progress for those impacted by this disease. Thank you to everyone who made it such a meaningful day!

The Gallop Oncology team will be onsite at #ESMO26, where Phase 1b results for LYT-200 will be presented in an oral proffered paper session. Guenther Koehne, MD, PhD, will highlight encouraging clinical activity and favorable safety observed in heavily pretreated patients with relapsed/refractory high-risk #MyelodysplasticSyndromes and #AcuteMyeloidLeukemia. These findings reinforce the potential of LYT-200 as a first-in-class, mutation-agnostic treatment option. Learn more about the upcoming presentation and Gallop’s plans to advance LYT-200 into Phase 2 development: bit.ly/4dKKqEd

We’re honored to be shortlisted for the 2026 @Citeline Biotech Awards in the category of Excellence in Rare Disease Drug Development. This recognition reflects our work advancing deupirfenidone, an investigational, next-generation antifibrotic with the potential to serve as a new standard of care for people living with #idiopathicpulmonaryfibrosis (#IPF). Deupirfenidone is now being advanced by our Founded Entity @CeleaTx through SURPASS-IPF: the first industry-sponsored head-to-head Phase 3 trial in IPF, which is evaluating the potential superiority of deupirfenidone against an approved antifibrotic. Congratulations to our fellow shortlisted companies on this recognition. We’re inspired by the breadth of scientific innovation represented and the shared commitment to advancing #raredisease treatments through close collaboration with patients, clinicians, and advocacy communities. Read more about the 2026 Citeline Biotech Awards: bit.ly/4dyaAtS

Today we announced our 2026 Half-Year results & will host a webcast at 9am BST. Read more: bit.ly/46COB0Y

Today, we announced two important milestones for LYT-200: Successful End-of-Phase 1 meeting with the FDA FDA Fast Track designation for R/R high-risk #MyelodysplasticSyndromes These achievements support advancement into the Phase 2 STRIDE-MDS trial. bit.ly/4yPOjjj #HRMDS

We’re honored to be nominated for a 2026 #PrixGalien USA Award in the Incubators, Accelerators and Equity category. This recognition reflects the strength of the model we have built at PureTech to identify high-potential therapeutic opportunities, advance and de-risk them, and form dedicated companies around the most promising programs – all with the goal of bringing important new medicines to patients. We’re proud that this approach has generated a portfolio of companies and dozens of therapeutic candidates, including three that have received FDA approval. Thank you to @GalienFdn for including us among this distinguished group of nominees. prn.to/4ci9pOk

Just days after announcing the financing for our Founded Entity @CeleaTx, we're pleased to share another important milestone. The first patient has been dosed in SURPASS-IPF, the first industry-sponsored head-to-head Ph3 trial in #idiopathicpulmonaryfibrosis, evaluating deupirfenidone. Read more: bit.ly/4w2ibYN